Search Results
You are looking at 1 - 3 of 3 items for
- Author: L Vinter-Jensen x
- Refine by access: All content x
Search for other papers by L Vinter-Jensen in
Google Scholar
PubMed
Search for other papers by C Orloff Juhl in
Google Scholar
PubMed
Search for other papers by J Frystyk in
Google Scholar
PubMed
Search for other papers by E Z Dajani in
Google Scholar
PubMed
Search for other papers by N Oksbjerg in
Google Scholar
PubMed
Search for other papers by A Flyvbjerg in
Google Scholar
PubMed
Abstract
It has recently been demonstrated that epidermal growth factor (EGF) administration to neonatal rodents causes growth retardation with concomitant reductions in circulation levels of IGF-I. We describe the effects of systemic EGF administration for 4 weeks on circulating levels of IGF-I and IGF-binding proteins (IGFBPs) and on thyroid hormones (tri-iodothyronine, T3; thyroxine, T4) in sexually mature pigs. Goettingen minipigs of either sex were treated with placebo (n=5) or EGF (30 μg/kg per day, n=6) s.c. for 4 weeks (in relation to an oesophageal sclerotherapy regimen). Blood samples were taken under anaesthesia before and after 1, 2, 3 and 4 weeks of treatment. Circulating levels of IGF-I, insulin, glucose, T3 and T4 were analysed every week and IGFBPs every second week. IGF-I was not reduced significantly after 1 week but significantly reduced after 2 and 3 weeks of EGF treatment. A similar decline was observed for the major IGFBP, IGFBP-3, which was reduced after 2 and 4 weeks. IGFBP-1, IGFBP-2 and IGFBP-4 increased throughout the treatment period (all significantly at week 4). EGF treatment induced increased circulating T3 after 2, 3 and 4 weeks of EGF treatment. In conclusion, we report that EGF treatment for 4 weeks in Goettingen minipigs reduces circulating IGF-I and IGFBP-3, increases circulating IGFBP-1, IGFBP-2 and IGFBP-4, and induces a slight hyperthyroidism as judged from increased circulating levels of T3.
Journal of Endocrinology (1996) 151, 401–407
Search for other papers by L Vinter-Jensen in
Google Scholar
PubMed
Search for other papers by J Frøkiær in
Google Scholar
PubMed
Search for other papers by P E Jørgensen in
Google Scholar
PubMed
Search for other papers by J Marqversen in
Google Scholar
PubMed
Search for other papers by M Rehling in
Google Scholar
PubMed
Search for other papers by E Z Dajani in
Google Scholar
PubMed
Search for other papers by E Nexø in
Google Scholar
PubMed
Abstract
We visualized the metabolism of intravenously injected 131I-labelled epidermal growth factor in the pig using dynamic scintigraphy combined with repetitive samplings of blood, urine and bile. The labelled peptide was recognized in the samples by means of immunoprecipitation and high pressure liquid chromatography. The plasma elimination was extremely rapid, and it was described with a triexponential equation, C(t)=A*e −α*t+B*e −β*t+ C*e −γ*t. The first two exponentials denoted the distribution phase, and the third the elimination phase. T1/2α ranged from 0·4–0·7 min, T1/2β from 2·0–2·2 min and T1/2γ from 53·3–97·6 min. Concomitant with the rapidly declining plasma concentration, the gamma camera visualized the uptake by the liver and the kidneys. The liver was the principal organ for clearance and degradation of the labelled peptide, but only 0·12–0·30% of the injected dose was excreted into the bile. The renal uptake and the urinary excretion accounted for 6·6–13·0 and 2·5–4·9% of the given dose, respectively.
Journal of Endocrinology (1995) 144, 5–12
Search for other papers by JW van Neck in
Google Scholar
PubMed
Search for other papers by EM Berghout in
Google Scholar
PubMed
Search for other papers by L Vinter-Jensen in
Google Scholar
PubMed
Search for other papers by CA Groffen in
Google Scholar
PubMed
Search for other papers by V Cingel in
Google Scholar
PubMed
Search for other papers by NF Dits in
Google Scholar
PubMed
Search for other papers by SL Drop in
Google Scholar
PubMed
Search for other papers by A Flyvbjerg in
Google Scholar
PubMed
Systemic administration of epidermal growth factor (EGF) in neonatal rats results in reduced body weight gain and decreased circulating levels of IGF-I, suggesting its involvement in EGF-induced growth retardation. We investigated the effect of EGF and/or IGF-I administration for 7 days on circulating IGF-I and IGFBP levels and hepatic and renal IGF-system mRNA expression profiles in adult female rats. EGF administration (30 microg/rat/day) did not influence body weight, liver or kidney weight. In contrast, IGF-I (400 microg/rat/day) and EGF/IGF-I administration increased both body weight and kidney weight. Also, serum IGF-I and the 30 kDa IGFBPs (IGFBP-1 and -2) were significantly increased in these groups. Serum IGFBP-3 levels increased in the IGF-I group along with increased hepatic IGFBP-1 and -3 mRNA levels. In contrast, in the EGF administration group serum IGFBP-3 levels were significantly decreased; however, the mRNA levels remained unchanged. In the EGF/IGF-I administration group, serum IGF-I and IGFBP-3 levels were significantly lowered when compared with the IGF-I administration group. This was in contrast to the effect on kidney weight increase that was identical for the IGF-I and EGF/IGF-I groups. The decrease in serum IGFBP-3 was not reflected at the hepatic IGFBP-3 mRNA level. IGFBP-3 expression might be regulated at a post-transcriptional level although EGF induced IGFBP-3 proteolysis could not be demonstrated in vitro. We conclude that EGF administration reduced serum IGFBP-3 whereas IGF-I administration increased the level of IGFBP-3 and IGF-I and resulted in an increased body and kidney weight in adult female rats.
